bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO.
| Revenue (Most Recent Fiscal Year) | $6.16M |
| Net Income (Most Recent Fiscal Year) | $-14.91M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.09 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -241.25% |
| Net Margin (Trailing 12 Months) | -241.93% |
| Return on Equity (Trailing 12 Months) | -301.67% |
| Return on Assets (Trailing 12 Months) | -142.38% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.58 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.08 |
| Inventory Turnover (Trailing 12 Months) | 98.57 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-15.76 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 4.50M |
| Free Float | 4.38M |
| Market Capitalization | $12.87M |
| Average Volume (Last 20 Days) | 5.53M |
| Beta (Past 60 Months) | -0.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.68% |
| Percentage Held By Institutions (Latest 13F Reports) | 1.64% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |